You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Acetaminophen; ibuprofen sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for acetaminophen; ibuprofen sodium and what is the scope of patent protection?

Acetaminophen; ibuprofen sodium is the generic ingredient in one branded drug marketed by Hikma and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Acetaminophen; ibuprofen sodium has sixty-five patent family members in thirty countries.

One supplier is listed for this compound.

Summary for acetaminophen; ibuprofen sodium
International Patents:65
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 7
DailyMed Link:acetaminophen; ibuprofen sodium at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for acetaminophen; ibuprofen sodium
Generic Entry Date for acetaminophen; ibuprofen sodium*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for acetaminophen; ibuprofen sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, Los AngelesPhase 4
Northwestern UniversityPhase 4
Nemours Children's ClinicEarly Phase 1

See all acetaminophen; ibuprofen sodium clinical trials

Pharmacology for acetaminophen; ibuprofen sodium

US Patents and Regulatory Information for acetaminophen; ibuprofen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma COMBOGESIC IV acetaminophen; ibuprofen sodium SOLUTION;INTRAVENOUS 215320-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma COMBOGESIC IV acetaminophen; ibuprofen sodium SOLUTION;INTRAVENOUS 215320-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hikma COMBOGESIC IV acetaminophen; ibuprofen sodium SOLUTION;INTRAVENOUS 215320-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma COMBOGESIC IV acetaminophen; ibuprofen sodium SOLUTION;INTRAVENOUS 215320-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma COMBOGESIC IV acetaminophen; ibuprofen sodium SOLUTION;INTRAVENOUS 215320-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hikma COMBOGESIC IV acetaminophen; ibuprofen sodium SOLUTION;INTRAVENOUS 215320-001 Oct 17, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for acetaminophen; ibuprofen sodium

Country Patent Number Title Estimated Expiration
China 113018258 包含对乙酰氨基酚和布洛芬的水性制剂 (Aqueous formulation comprising paracetamol and ibuprofen) ⤷  Sign Up
European Patent Office 2635269 COMPOSITION COMBINÉE (A COMBINATION COMPOSITION) ⤷  Sign Up
South Korea 101900520 ⤷  Sign Up
Portugal 2635269 ⤷  Sign Up
Canada 2955557 FORMULATION AQUEUSE COMPRENANT DU PARACETAMOL ET DE L'IBUPROFENE (AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN) ⤷  Sign Up
China 106794163 包含对乙酰氨基酚和布洛芬的水性制剂 (Aqueous formulation comprising paracetamol and ibuprofen) ⤷  Sign Up
Australia 2015289035 Aqueous formulation comprising paracetamol and ibuprofen ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.